Association of Healthcare Providers Welcomes the Cabinet Committee Approved Officially Amended National Medical Commission (NMC) Bill 2017

admin
admin
· 3 min read
stock NEET PG Results

The Government has accepted the recommendations made by the Parliamentary Standing Committee in its report tabled in the Parliament on 20.03.2018 particularly those relating to medical students and practitioners regarding certain critical provisions of the Bill. The newly amended  NMC Bill 2017 brings into sharp focus the vision and priority of the present Government aimed at rejuvenating the healthcare sector in India and fulfills the objectives of having a world-class regulatory framework in relation to medical education in India.The Union Cabinet Committee chaired by Prime Minister Shri Narendra Modi approved the following amendments.

Firstly, taking a humane approach the cabinet committee accepted the demand of medical students and medical practitioners and arrived at the decision of not subjecting medical students to an additional licentiate exam for the purpose of acquiring license to practice, final MBBS Examination to be held as a common exam across the country and would serve as an exit test called the National Exit Test (NEXT). NEXT would also serve as the screening test for doctors with foreign medical qualifications in order to practice in India.

Secondly, the maximum limit of 40% seats for which fee would be regulated in private medical institutions and deemed universities has been increased to 50% seats. Further, it has been clarified that the fee would also include all other charges taken by the colleges.

Thirdly, taking into account the demands from States to increase their representation in the NMC, the nominees of States and UTs in the NMC have been increased from 3 to 6. The NMC will comprise of 25 members of which at least 21 will be doctors.

Fourthly, monetary penalty for a medical college non-compliant with the norms replaced with a provision which provides different options for a warning, reasonable monetary penalty, reducing intake, stoppage of admission leading up to the withdrawal of recognition.

Fifthly, since the government is concerned about the quality and safety of healthcare being made available to the citizens, punishment for any unauthorized practice of medicine/quackery has been made strict by including a provision for an imprisonment of up to one year along with a fine extending up to Rs. 5 lakhs.

The newly amended NMC Bill assumes immense significance in view of the abject failure of the  Medical Council of India as the regulator of medical education in the country, resulting in innumerable challenges to the healthcare industry in India, shortage of doctors including specialists and super specialists in adequate numbers and of requisite quality; deficiency of teachers in medical colleges, disconnect between medical education system and healthcare system; geographical mal-distribution of medical colleges; poor regulation of Undergraduate (UG) and Postgraduate (PG) education, unaccountability to name a few.

In view of the fact that, the current situation in the healthcare sector has gone far beyond the point of incremental tweaking of the present system, Association of Healthcare Providers, India, (AHPI) welcomes the newly amended National Medical Commission Bill (NMC Bill) 2017 as a game changer reform initiative of transformational nature, as such the need of the hour for both medical education system and healthcare industry.

Read Next

Alembic Pharmaceuticals announces USFDA Tentative Approval for Darolutamide Tablets
News
May 14, 2026

Alembic Pharmaceuticals announces USFDA Tentative Approval for Darolutamide Tablets

Alembic Pharmaceuticals Limited (Alembic) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darolutamide Tablets, 300 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nubeqa Tablets, 300 mg, of Bayer HealthCare Pharmaceuticals Inc. (Bayer). Darolutamide is an androgen […]
Article by: IMT News Desk
Lilly launches Lormalzi® (Donanemab) for the treatment of early symptomatic Alzheimer’s Disease in India
News
May 14, 2026

Lilly launches Lormalzi® (Donanemab) for the treatment of early symptomatic Alzheimer’s Disease in India

Eli Lilly and Company (India) Pvt. Ltd. has announced the launch of Lormalzi® (donanemab, 350 mg/20 mL IV vial) in India, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for the treatment of Alzheimer’s disease with mild cognitive impairment or those in the mild dementia stage of disease. Lormalzi® is the first […]
Article by: IMT News Desk
Stryker and Max Smart Hospital, Saket Partner to Advance Surgeon Training and Education in Robotic-Arm Assisted Joint Replacement
News
May 14, 2026

Stryker and Max Smart Hospital, Saket Partner to Advance Surgeon Training and Education in Robotic-Arm Assisted Joint Replacement

Stryker and Max Smart Super Speciality Hospital, Saket, announced a strategic collaboration to advance surgeon training, clinical education, and patient care in robotic-arm-assisted joint replacement in India. As part of this collaboration, Max Smart Super Speciality Hospital, Saket, will serve as a training and education center for orthopaedics. The collaboration aims to support the evolving joint replacement ecosystem […]
Article by: IMT News Desk
World’s First Subcutaneous Immunotherapy for Lung Cancer- Tecentriq® SC, now available in India
News
May 14, 2026

World’s First Subcutaneous Immunotherapy for Lung Cancer- Tecentriq® SC, now available in India

Roche Pharma India has launched Tecentriq® (atezolizumab) SC in India, the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately 7 minutes, compared to conventional IV infusions that can take hours. By reducing treatment administration time to approximately 7 minutes, Tecentriq SC is a breakthrough innovation that has the potential […]
Article by: IMT News Desk